- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Breast Cancer, Sarcoma, Bladder Cancer, Lung Cancer, Prostate Cancer, Cervical Cancers, Head and Neck Cancers, Adrenal Gland Tumors
- Interventions
- IDOV-Immune (oncolytic vaccinia virus)
- Biological
- Lead sponsor
- ViroMissile, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Houston, Texas • San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 2,369
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- Focused Microwave Thermotherapy, Chemotherapy (control)
- Device · Drug
- Lead sponsor
- Medifocus, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Breast Cancer
- Interventions
- docetaxel, protein expression analysis, laboratory biomarker analysis, biopsy, conventional surgery, neoadjuvant therapy
- Drug · Genetic · Other + 1 more
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee
- Conditions
- Persistent Postsurgical Pain, Breast Cancer Female, Ductal Carcinoma in Situ
- Interventions
- Acceptance and Commitment Therapy
- Behavioral
- Lead sponsor
- Katherine Hadlandsmyth
- Other
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Breast Neoplasm Female
- Interventions
- Oculus Go Virtual Reality Goggles
- Device
- Lead sponsor
- Prisma Health-Upstate
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Greenville, South Carolina
- Conditions
- Breast Cancer, Healthy, no Evidence of Disease
- Interventions
- Random fine need aspiration (rFNA), Mammogram
- Procedure · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 35 Years to 60 Years · Female only
- Enrollment
- 385 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Extensive Stage Small Cell Lung Cancer (ES-SCLC), NSCLC
- Interventions
- IDE-161, Pembrolizumab
- Drug
- Lead sponsor
- IDEAYA Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 22 more
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma
- Interventions
- Biospecimen Collection, Educational Intervention, Extended Release Metformin Hydrochloride, Questionnaire Administration
- Procedure · Other · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 3
- States / cities
- Duarte, California • La Jolla, California • Riverside, California
- Conditions
- Breast Cancer
- Interventions
- Mammography Screening Conversation Aid
- Behavioral
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 75 Years to 89 Years · Female only
- Enrollment
- 155 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hodgkins Disease
- Interventions
- Proton
- Radiation
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 10 Years to 30 Years · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Bloomington, Indiana
- Conditions
- Gestational Diabetes Mellitus (GDM), Diabetes Type 2, Breastfeeding Continuation, Breastfeeding Support
- Interventions
- Implementation mapping to develop a multilevel health system strategy for prevention of type 2 diabetes through targeted breastfeeding support for patients with gestational diabetes
- Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Breast Cancer, Breast Cancer Metastatic
- Interventions
- Educational Brochure
- Behavioral
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Breast Cancer
- Interventions
- CyberKnife Partial Breast Irradiation
- Radiation
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 45 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Breast Cancer Female, Chemotherapy-induced Peripheral Neuropathy, Gait Disorders, Neurologic, Balance; Distorted, Muscle Weakness
- Interventions
- Gait/balance & resistive exercise
- Behavioral
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Recurrent or Metastatic Solid Tumors
- Interventions
- Ifinatamab deruxtecan
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 680 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Whittier, California • Skokie, Illinois + 13 more
- Conditions
- Estrogen Receptor Positive, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Fulvestrant, Laboratory Biomarker Analysis, Lapatinib Ditosylate, Placebo Administration
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 368
- States / cities
- Little Rock, Arkansas • Arroyo Grande, California • Burbank, California + 259 more
- Conditions
- Receptors, Estrogen, Genes, Erbb-2, Breast Neoplasms
- Interventions
- Palbociclib (75, 100, 125 milligram [mg]), H3B-6545 (150, 300, 450 mg)
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 5
- States / cities
- Sarasota, Florida • Boston, Massachusetts • Kansas City, Missouri + 2 more
- Conditions
- Breast Cancer
- Interventions
- Comprehensive Health Enhancement Support System (CHESS.)
- Behavioral
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Breast Cancer
- Interventions
- gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride
- Drug
- Lead sponsor
- Pharmatech Oncology
- Industry
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 6
- States / cities
- Montgomery, Alabama • West Covina, California • Denver, Colorado + 2 more
- Conditions
- Breast Cancer
- Interventions
- Tecemotide (L-BLP25) and Hormonal Treatment, Placebo of tecemotide (L-BLP25) and Hormonal Treatment, cyclophosphamide, sodium chloride (NaCl)
- Biological · Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Hickory, North Carolina
- Conditions
- Cervical Cancer, Breast Cancer, Colorectal Cancer
- Interventions
- Cancer risk communication skills training
- Other
- Lead sponsor
- Tulane University School of Medicine
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 5
- States / cities
- New Orleans, Louisiana
- Conditions
- Breast Neoplasms, Breast Cancer, Cancer of Breast, Cancer of the Breast
- Interventions
- Bright blue-green light using light visor cap, Dim red light using light visor cap, European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire, Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance, Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue, Digital foot candle datalogging light meter (Extech Instrument, Model SDL400), Polysomnography (Easy Ambulatory 2 Cadwell, Kennewick, WA), Horne-Ostberg Morningness-Eveningness Questionnaire, Daily Fatigue and Sleep Log
- Other · Diagnostic Test
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Gastric/Gastroesophageal Junction (GEJ) Cancer, Bladder Cancer
- Interventions
- [68Ga]Ga-DWJ155, [177Lu]Lu-DWJ155
- Diagnostic Test · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- HIV Infection, Recurrent Anal Cancer, Recurrent Breast Cancer, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Anal Cancer, Stage IV Breast Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- vorinostat, diagnostic laboratory biomarker analysis, pharmacological study, carboplatin, paclitaxel
- Drug · Other
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 10
- States / cities
- La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 7 more